Table 2.
Baseline characteristics of the real-world HFpEF cohort as compared to PARAGON-HF.
| Characteristic | Real-World HFpEF Cohort n = 427 |
PARAGON-HF Cohort n = 4796 |
|---|---|---|
| Age—years | 72.0 ± 8.4 | 72.8 ± 8.4 |
| Female sex—no. (%) | 299 (70.0) | 2479 (51.7) |
| Systolic blood pressure—mmHg * | 140.0 ± 21.3 | 130.6 ± 15.5 |
| Heart rate—beats/min | 71.6 ± 14.1 | 70.5 ± 12.3 |
| Body-mass index—kg/m2 | 30.0 ± 6.3 | 30.3 ± 5.0 |
| Serum creatinine—mg/dL | 1.2 ± 0.6 | 1.1 ± 0.3 |
| Estimated GFR—mL/min/1.73 m2 * | 59.2 ± 23.3 | 62.5 ± 19.0 |
| Clinical features of heart failure | ||
| Left ventricular ejection fraction—% * | 60.3 ± 7.9 | 57.6 ± 7.9 |
| Median NT-proBNP (interquartile range)—pg/mL | 1064 (438–2002) | 910 (464–1611) |
| NYHA functional class—no. (%) | ||
| I | 11 (2.6) | 137 (2.9) |
| II | 155 (36.3) | 3706 (77.2) |
| III | 238 (55.7) | 932 (19.4) |
| IV | 23 (5.4) | 19 (0.4) |
| Missing data | 0 (0.0) | 2 (0.1) |
| Medical history—no. (%) | ||
| Hypertension | 401 (93.9) | 4584 (95.6) |
| Diabetes | 146 (34.2) | 2062 (43.0) |
| Atrial fibrillation or flutter † | 248 (58.1) | 1552 (32.4) |
| Hospitalization for heart failure * | 91 (21.3) | 2306 (48.1) |
| Treatment—no. (%) | ||
| Diuretic agent * | 361 (84.5) | 4585 (95.6) |
| ACE inhibitor or ARB | 297 (69.6) | 4139 (86.3) |
| Mineralocorticoid receptor antagonist | 179 (41.9) | 1239 (25.8) |
| Beta-blocker | 314 (73.5) | 3821 (79.7) |
Values are given as mean ± standard deviation, or median and interquartile range, or total numbers and percent. GFR indicates glomerular filtration rate; NYHA, New York Heart Association; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker. * Between-cohort differences due to different inclusion and exclusion criteria (Table 1). † Number of patients with atrial fibrillation was limited to approximately 33% in PARAGON-HF.